NGM Biopharmaceuticals
Metabolic/fibrotic disease therapeutics
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | ILT2 and ILT4 (immunoglobulin-like transcript receptors 2 and 4)Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-Q3 | $0.6M | $23M | $57M | $29M | report ↗ |
NGM Biopharmaceuticals reported revenue of $0.58M, down 92.7% YoY, R&D spend of $22.94M, down 50.2% YoY, cash and equivalents of $56.93M, and a quarterly net burn of $28.8M for Q3 2023.
Figures only: this period's report disclosed no narrative text
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-Q2 | $1.4M | $32M | $57M | $38M | report ↗ |
| 2023-Q1 | $2.3M | $41M | $72M | $48M | report ↗ |
| 2022-Q3 | $7.9M | $46M | $105M | $47M | report ↗ |
| 2022-Q2 | $8.3M | $45M | $65M | $47M | report ↗ |
| 2022-Q1 | $21M | $43M | $111M | $32M | report ↗ |
| 2021-Q3 | $19M | $39M | $147M | $29M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-FY | $4.4M | $118M | $61M | $142M | report ↗ |